( MENAFN - GlobeNewsWire - Nasdaq) Planegg/Martinsried, May 28, 2024 – Medigene AG (Medigene or the“Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today announced the submission of three patents to the European Patent Office. This underscores Medigene's commitment to advancing T cell-based immunotherapies for the treatment of solid tumors. Interferon-Gamma (IFNγ) Biosensor The first patent submission covers the Company's innovative Interferon-gamma (IFNγ) Biosensor, a technology that enables real-time monitoring and quantification of IFNγ release from cytokine-secreting cells.
The proprietary technology allows to better understand immune response dynamics by utilizing a simplified and efficient cytometry detection method. The IFNγ Biosensor technology overcomes the limitations of currently available commercial tools, which are often costly, time-consuming, and prone to errors due to complex procedures that diminish reproducibility. Additionally, conventional methods typically only allow for endpoint measurements and do not support real-time monitoring of IFNγ over extended periods which is made possible through use of this IFNγ Biosensor.
High Precision TCR Tracking (UniTope & TraCR) Additionally, Medigene has filed two patents for its novel T cell receptor (TCR)-specific Antigen-Antibody combination technology, UniTope & TraCR. This technology incorpor.
